AR and prostate carcinoma: Proposed mechanisms of HDAC inhibitor clinical activity in prostate cancer include: preferential targeting of HDAC6 which deacetylates HSP90 and decreases AR stability, direct suppression of AR transcription, and sensitization of prostate cancer cells to DNA-damaging agents by targeting Ku70 acetylation [101, 103–105].